Entering text into the input field will update the search result below

ALPMF Astellas Pharma Inc.
Stock Price & Overview

$14.49-0.27 (-1.83%)10:51 AM 09/25/23
Pink Limited Info | $USD | Market Close


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

Ratings Summary

Now6M ago
SA Analysts
Not CoveredRating: Not Covered
Wall Street
Not CoveredRating: Not Covered
Not CoveredRating: Not Covered

Ratings Summary

SA Analysts
Wall Street

See ALPMF ratings with Premium.

Company Profile

Astellas Pharma Inc. logo
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. The company was founded in 1923 and is headquartered in Tokyo, Japan.
  • 2-5-1, Nihonbashi-Honcho
  • Chuo-Ku
  • Tokyo, 103-8411
  • Japan
Phone Number
81 3 3244 3000
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.